Cargando…

Evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚C in the treatment of peritoneal metastasis: A pilot study

While hyperthermic intraperitoneal applications have demonstrated high efficacy in treating peritoneal metastases (PM), these applications are limited to temperatures of 41-43˚C to prevent a harmful increase in core temperature. However, since gaseous substances display low specific heat capacities,...

Descripción completa

Detalles Bibliográficos
Autores principales: Thelen, Simon, Mikolajczyk-Martinez, Agata, Diakun, Agata, Khosrawipour, Tanja, Zielinski, Kacper, Nicpoń, Jakub, Kiełbowicz, Zdzisław, Prządka, Przemysław, Liszka, Bartłomiej, Kuropka, Piotr, Li, Shiri, Lau, Hien, Kielan, Wojciech, Khosrawipour, Veria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748640/
https://www.ncbi.nlm.nih.gov/pubmed/36561969
http://dx.doi.org/10.3892/etm.2022.11687
_version_ 1784849866216701952
author Thelen, Simon
Mikolajczyk-Martinez, Agata
Diakun, Agata
Khosrawipour, Tanja
Zielinski, Kacper
Nicpoń, Jakub
Kiełbowicz, Zdzisław
Prządka, Przemysław
Liszka, Bartłomiej
Kuropka, Piotr
Li, Shiri
Lau, Hien
Kielan, Wojciech
Khosrawipour, Veria
author_facet Thelen, Simon
Mikolajczyk-Martinez, Agata
Diakun, Agata
Khosrawipour, Tanja
Zielinski, Kacper
Nicpoń, Jakub
Kiełbowicz, Zdzisław
Prządka, Przemysław
Liszka, Bartłomiej
Kuropka, Piotr
Li, Shiri
Lau, Hien
Kielan, Wojciech
Khosrawipour, Veria
author_sort Thelen, Simon
collection PubMed
description While hyperthermic intraperitoneal applications have demonstrated high efficacy in treating peritoneal metastases (PM), these applications are limited to temperatures of 41-43˚C to prevent a harmful increase in core temperature. However, since gaseous substances display low specific heat capacities, gas-based hyperthermia could potentially increase surface temperatures without affecting the body's core temperature. To the best of our knowledge, the present study is the first to explore the in vivo feasibility of gas-based hyperthermia via spatial and time-based distribution. In the present study, a temperature-isolated, abdominal box model was created with fresh peritoneal tissue exposed to continuous high-volume airflow temperatures ranging between 47 and 69˚C. Heat conduction within the peritoneal tissues was measured using temperature microsensors. Temperature build-up at different time points during the procedure was calculated and the safest option to perform gas-based intraperitoneal hyperthermia beyond 43˚C was identified using an in vivo swine model. In subsequent experiments, viability and cytotoxicity of HT-29 colon cancer cells were measured following short-term hyperthermia. The present study demonstrated that the application of gas-based intraperitoneal hyperthermia with temperatures up to 50˚C is possible without increasing the core temperature to harmful levels. Gas-based intraperitoneal hyperthermia can induce a histological reaction on the peritoneal surface, and it can also result in decreased viability and increased cytotoxicity of HT-29 cells. The concept of extreme hyperthermia may be of great clinical importance as it could significantly increase local cytotoxicity in PM without increasing the body's core temperature. Further studies are required to investigate the benefits, as well as the restrictions, of this novel concept.
format Online
Article
Text
id pubmed-9748640
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-97486402022-12-21 Evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚C in the treatment of peritoneal metastasis: A pilot study Thelen, Simon Mikolajczyk-Martinez, Agata Diakun, Agata Khosrawipour, Tanja Zielinski, Kacper Nicpoń, Jakub Kiełbowicz, Zdzisław Prządka, Przemysław Liszka, Bartłomiej Kuropka, Piotr Li, Shiri Lau, Hien Kielan, Wojciech Khosrawipour, Veria Exp Ther Med Articles While hyperthermic intraperitoneal applications have demonstrated high efficacy in treating peritoneal metastases (PM), these applications are limited to temperatures of 41-43˚C to prevent a harmful increase in core temperature. However, since gaseous substances display low specific heat capacities, gas-based hyperthermia could potentially increase surface temperatures without affecting the body's core temperature. To the best of our knowledge, the present study is the first to explore the in vivo feasibility of gas-based hyperthermia via spatial and time-based distribution. In the present study, a temperature-isolated, abdominal box model was created with fresh peritoneal tissue exposed to continuous high-volume airflow temperatures ranging between 47 and 69˚C. Heat conduction within the peritoneal tissues was measured using temperature microsensors. Temperature build-up at different time points during the procedure was calculated and the safest option to perform gas-based intraperitoneal hyperthermia beyond 43˚C was identified using an in vivo swine model. In subsequent experiments, viability and cytotoxicity of HT-29 colon cancer cells were measured following short-term hyperthermia. The present study demonstrated that the application of gas-based intraperitoneal hyperthermia with temperatures up to 50˚C is possible without increasing the core temperature to harmful levels. Gas-based intraperitoneal hyperthermia can induce a histological reaction on the peritoneal surface, and it can also result in decreased viability and increased cytotoxicity of HT-29 cells. The concept of extreme hyperthermia may be of great clinical importance as it could significantly increase local cytotoxicity in PM without increasing the body's core temperature. Further studies are required to investigate the benefits, as well as the restrictions, of this novel concept. D.A. Spandidos 2022-11-08 /pmc/articles/PMC9748640/ /pubmed/36561969 http://dx.doi.org/10.3892/etm.2022.11687 Text en Copyright: © Thelen et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Thelen, Simon
Mikolajczyk-Martinez, Agata
Diakun, Agata
Khosrawipour, Tanja
Zielinski, Kacper
Nicpoń, Jakub
Kiełbowicz, Zdzisław
Prządka, Przemysław
Liszka, Bartłomiej
Kuropka, Piotr
Li, Shiri
Lau, Hien
Kielan, Wojciech
Khosrawipour, Veria
Evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚C in the treatment of peritoneal metastasis: A pilot study
title Evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚C in the treatment of peritoneal metastasis: A pilot study
title_full Evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚C in the treatment of peritoneal metastasis: A pilot study
title_fullStr Evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚C in the treatment of peritoneal metastasis: A pilot study
title_full_unstemmed Evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚C in the treatment of peritoneal metastasis: A pilot study
title_short Evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚C in the treatment of peritoneal metastasis: A pilot study
title_sort evaluating the concept of gas‑based intraperitoneal hyperthermia beyond 43˚c in the treatment of peritoneal metastasis: a pilot study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748640/
https://www.ncbi.nlm.nih.gov/pubmed/36561969
http://dx.doi.org/10.3892/etm.2022.11687
work_keys_str_mv AT thelensimon evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT mikolajczykmartinezagata evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT diakunagata evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT khosrawipourtanja evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT zielinskikacper evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT nicponjakub evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT kiełbowiczzdzisław evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT przadkaprzemysław evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT liszkabartłomiej evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT kuropkapiotr evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT lishiri evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT lauhien evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT kielanwojciech evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy
AT khosrawipourveria evaluatingtheconceptofgasbasedintraperitonealhyperthermiabeyond43cinthetreatmentofperitonealmetastasisapilotstudy